GSK (LON:GSK) Given Buy Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their buy rating on shares of GSK (LON:GSK) in a research report released on Wednesday, Marketbeat.com reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,950 ($24.27) price target on the stock.

Other equities analysts also recently issued reports about the stock. Barclays reaffirmed an equal weight rating and set a GBX 1,725 ($21.47) price objective on shares of GSK in a report on Monday, April 8th. Berenberg Bank lifted their price target on shares of GSK from GBX 1,650 ($20.54) to GBX 1,820 ($22.66) and gave the company a buy rating in a report on Wednesday, February 14th. Finally, Shore Capital reissued a buy rating on shares of GSK in a report on Thursday, March 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, GSK currently has a consensus rating of Hold and an average price target of GBX 1,630.63 ($20.30).

GSK Price Performance

LON:GSK opened at GBX 1,588.50 ($19.77) on Wednesday. The company has a 50-day moving average of GBX 1,663.74 and a 200-day moving average of GBX 1,545.06. The company has a market capitalization of £64.97 billion, a price-to-earnings ratio of 1,325.00, a PEG ratio of 1.09 and a beta of 0.27. GSK has a 52 week low of GBX 1,302.60 ($16.22) and a 52 week high of GBX 1,719.80 ($21.41). The company has a debt-to-equity ratio of 140.82, a quick ratio of 0.73 and a current ratio of 0.88.

GSK Increases Dividend

The company also recently declared a dividend, which was paid on Thursday, April 11th. Investors of record on Thursday, February 22nd were issued a dividend of GBX 16 ($0.20) per share. This is an increase from GSK’s previous dividend of $14.00. This represents a yield of 1.04%. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is currently 5,333.33%.

Insiders Place Their Bets

In related news, insider Julie Brown bought 19,360 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was bought at an average cost of GBX 1,583 ($19.71) per share, with a total value of £306,468.80 ($381,512.26). In other GSK news, insider Emma Walmsley sold 139,792 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.64), for a total value of £2,317,751.36 ($2,885,287.39). Also, insider Julie Brown bought 19,360 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was bought at an average cost of GBX 1,583 ($19.71) per share, with a total value of £306,468.80 ($381,512.26). Over the last three months, insiders purchased 19,802 shares of company stock valued at $31,381,484. Insiders own 1.71% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.